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In silicoa b s t r a c t
SARS-CoV-2, previously named 2019 novel coronavirus (2019-nCoV), has been associated with the global
pandemic of acute respiratory distress syndrome. First reported in December 2019 in the Wuhan pro-
vince of China, this new RNA virus has several folds higher transmission among humans than its other
family member (SARS-CoV and MERS-CoV). The SARS-CoV-2 spike receptor-binding domain (RBD) is
the region mediating the binding of the virus to host cells via Angiotensin-converting enzyme 2
(ACE2), a critical step of viral. Here in this study, we have utilized in silico approach for the virtual screen-
ing of antiviral library extracted from the Asinex database against the Receptor binding domain (RBD) of
the S1 subunit of the SARS-CoV-2 spike glycoprotein. Further, the molecules were ranked based on their
binding affinity against RBD, and the top 15 molecules were selected. The affinity of these selected mole-
cules to interrupt the ACE2-Spike interaction was also studied. It was found that the chosen molecules
were demonstrating excellent binding affinity against spike protein, and these molecules were also very
effectively interrupting the ACE2-RBD interaction.
Furthermore, molecular dynamics (MD) simulation studies were utilized to investigate the top 3
selected molecules’ stability in the ACE2-RBD complexes. To the best of our knowledge, this is the first
study where molecules’ inhibitory potential against the Receptor binding domain (RBD) of the S1 subunit
of the SARS-CoV-2 spike glycoprotein and their inhibitory potential against the ACE2-Spike has been
studied. We believe that these compounds can be further tested as a potential therapeutic option against
COVID-19.
 2021 The Author(s). Published by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
1.1. Background
To date we have identified three different human coronaviruses
(CoVs) (Zhu et al., 2020; Decaro and Lorusso, 2020; Coleman and
Frieman, 2014). First reported in 2002, the Severe acute respiratory
syndrome (SARS-CoV) was the first identified member of this
highly pathogenic coronavirus family (Zhu et al., 2020; Arshad
Ali et al., 2020). Other members of this family include the Middle
East respiratory syndrome coronavirus (MERS-CoV), which was
identified in 2012 (Arshad Ali et al., 2020; Oh et al., 2018). Both
SARS-CoV and MERS-CoV are capable of human-to-human trans-
mission and were responsible for the outbreak in 2003 and 2012,
respectively (Zhu et al., 2020; Oh et al., 2018; Docea et al., 2020).
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nCoV), has been associated with the global pandemic of acute res-
piratory distress syndrome (Lai et al., 2020). First reported in
December 2019 in the Wuhan province of China this new RNA
virus has several folds higher transmission among humans than
its other family members (SARS-CoV and MERS-CoV) (Lu et al.,
2020; Li et al., 2020; Wang et al., 2020). Declared as a global pan-
demic by WHO, the disease caused by this virus (SARS-CoV-2) was
termed as Coronavirus Disease 2019 (COVID-19). The person
infected with SARS-CoV-2 is shown to be showing a wide range
of symptoms, leading to respiratory, gastrointestinal diseases,
and even death (Wang et al., 2020; Chang et al., 2020). As of
27th October 2020, a total of 43.4 million confirmed cases of
COVID-19 were reported worldwide, which includes 1.16 million
deaths. This major suffering of the worldwide population due to
SARS-CoV-2 mediated disease has raised the alarm for the instant
call for antiviral drugs for treatment/prevention against COVID-19.
Belonging to the Coronaviridae family of order Nidovirales, CoV
has been classified into different genera which include a-, b-, c-,
and d-coronaviruses (Woo et al., 2009; Woo et al., 2012). Among
these different genera, a- b- and d- CoVs infects the mammals,
while the c-coronaviruses mainly infect avian species
(Mihindukulasuriya et al., 2008; Woo et al., 2009). The d-
coronaviruses are also reported to be infecting aves as well
(Naqvi et al., 2020). Coronaviruses are comprised of the largest
RNA viral genome (26-32 kb) (Li et al., 2020; Khan et al., 2020).
The genomes of Coronaviruses share a significant similarity; for
instance, the SARS-CoV-2 genome share ~82% similarity with the
SARS-CoV and MERS-CoV. This high level of sequence similarity
leads to these coronaviruses’ common pathogenesis mechanism,
and thus therapeutic targeting (Naqvi et al., 2020; Khan et al.,
2020). The viral genome of SAR-CoV-2 encodes for several struc-
tural as well as non-structural proteins. There are four structural
proteins in SARS-CoV-2, that include envelope (E), membrane
(M), spike (S), and nucleocapsid (N) proteins, which are playing a
prominent role in the viral assembly (Tai et al., 2020; Du et al.,
2016) (Fig. 1). These structural proteins are found to be sharing
high sequence similarity with their SARS-CoV, and MERS-CoV
counterparts. Among all the structural proteins, the main role is
played by the S protein, which is responsible for the cell membrane
fusion, viral attachment, and viral entry. These features of S protein
make it an important therapeutic target (Du et al., 2009; Du et al.,
2017; Li et al., 2005). The S1 subunit of S protein (RBD region)
binds to the host receptor, Angiotensin-converting enzyme 2
(ACE2), while the S2 subunit mediates the viral cell membrane
fusion (Li et al., 2005; Lu et al., 2013) (Fig. 1). Studies have found
that, like SARS-CoV, SARS-CoV-2 also utilizes the same host viral
entry mechanism where its homotrimeric spike (S) glycoprotein
binds to the host ACE2 (its functional host receptor) (Yi et al.,
2020; Zhou et al., 2020; Li et al., 2003). The Receptor binding
domain (RBD) of the S protein is the region involved in the most
critical step of viral entry within the target host cell i.e., it is the
region that mediates the binding of the virus to host cells (Li
et al., 2003; Othman et al., 2020). Here in this study, we have uti-
lized in silico approach for the virtual screening of Asinex antiviral
compound library against the RBD of the S1 subunit of the SARS-
CoV-2 spike glycoprotein.
Further, the molecules were ranked based on their binding
affinity against RBD, and the top 15 molecules were selected. The
affinity of these selected molecules to disrupt the ACE2-RBD inter-
action was also studied. Our study shows that the selected mole-
cules demonstrate very good binding affinity against spike
protein and effectively disrupt the ACE2-RBD interaction as well.
Furthermore, molecular dynamics (MD) simulation studies
were utilized to study the top 3 selected compounds’ stability in
the ACE2-RBD complexes. This is the first study, where the inhibi-3263tory potential of molecules against the RBD of the S1 subunit of the
SARS-CoV-2 spike glycoprotein and their inhibitory potential
against the ACE2-RBD has been studied. We believe that these
compounds may be a potential therapeutic option for the treat-
ment of COVID-19.
2. Material and methods
The 3D structure of Spike protein (RBD) in complex with the
human ACE-2 was retrieved from the RCSB protein data bank
(pdb id: 6m0j) (Burley et al., 2018; Lan et al., 2020). Further both
the RBD and ACE-2 were separated and the HEATM and other sol-
vent molecules were removed. The separated structure of Spike
protein (RBD) was considered for the virtual screening of antiviral
compounds. The antiviral library comprising of 6827 antiviral com-
pounds was downloaded from the Asinex database. Further, the
library was screened against the SARS-CoV-2 spike protein. The
virtual screening was performed using CCDC Gold (Jones et al.,
1997), and the molecules were ranked based on their PLP Fitness
score. The top selected molecules in complex with the SARS-CoV-
2 spike protein were considered for further study.
3. Protein-protein interaction
The spike receptor-binding domain (Chain E) and ACE-2 (Chain
A) were separated from the 3D complexed structure of ACE-2-RBD
(pdb id: 6m0j). The separated structures of Spike protein (RBD) and
human ACE-2 were redocked using Patchdock (Schneidman-
Duhovny et al., 2005). The generated results were further refined
for 1000 steps using firedock (Mashiach et al., 2008). The top-
scoring complex was selected based on the global energy score
and was compared to its crystal counterpart. The global energy
of this complex was taken as a reference for further study.
Further, the protein–protein interaction study was performed
using the same protocol, but this time the top-scoring molecules
in complex with the Spike protein (RBD) were docked against the
human ACE-2. The global score of all the complexes was compared
with the reference score.
4. Molecular dynamics simulation
The structure of Spike protein (RBD) in complex with the
human ACE-2 in the presence of the top selected compound was
further subjected to MD simulation studies using DESMOND
(Bowers et al., 2006). Here in this study, the OPLS3 force field
was used to perform the MD simulation studies (Robertson et al.,
2019). The first step was building the simulation systems using
the OPLS3 force field for proteins, followed by their SPC solvation
in the Orthorhombic box. Further, the counter ions were added
for neutralizing the systems. A series of energy minimization steps
were performed to relax the system. MD was performed for 10 ns
using NPT ensemble. The backbone root mean square deviation
(RMSD) plot for proteins, and the ligand was calculated using the
initial starting structure as a reference frame. Likewise, the root
mean square fluctuation (RMSF) was also calculated.
5. Result
The present study was focused on finding the potent inhibitor
candidates against the RBD of the S1 subunit of the SARS-CoV-2
spike glycoprotein. We further assessed the potential of these
selected inhibitor candidates to disrupt the binding of RBD to the
ACE2 receptor (Table 2). The flow chart of the complete work is
shown in Fig. 2. The library of 6827 molecules was screened
against the S-protein (RBD) of SARS-CoV-2. The molecules were
Fig. 1. The life cycle of SARS-CoV-2 in host cells.
Fig. 2. The virtual screening protocol used in this study. The structure of ACE2 is
shown in cyan color, while the structure of Receptor binding domain (RBD) SARS-
CoV-2 spike glycoprotein is in yellow color.
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Compound59910 78.72 T500, N501 R403, Y495, F497, N501,
G502, Y505
’Compound66040 77.51 Y453, G496,
Q498, G502
R403, Y495, N501, G502, Y505
’Compound66060 76.34 Y453, G496,
Q498, G502
R403, Y495, N501, G502, Y505
’Compound66120 75.45 Y453, G496,
Q498
R403, Y495, G496, N501,
G502, V503, Y505,
’Compound960 74.59 Y453, G502 R403, Y449, Q493, Y495,
F497, N501, Y505
’Compound1100 74.17 Y453, Q493 R403, Q493, Y495, F497,
N501, Y505
’Compound1070 73.13 R403, Y453 R403, K417, Y453, Y495, F497,
N501, Y505
’Compound7240 72.95 Y453, N501 R403, Y449, Q493, S494,
Y495, F497, N501, Y505
’Compound7080 72.77 Y453, G496,
Y505
R403, Q493, S494, Y495,
N501, Y505
’Compound1060 72.7 R403, Y453,
G496, N501
R403, K417, Y495, F497,
N501, Y505
’Compound7030 72.22 Y453, Y505 R403, Y449, Q493, S494,
Y495, G496, Y505
’Compound1480 72.08 R403, Y453 R403, K417, L455, Y495, F497,
N501, Y505
’Compound590 71.84 R403, Y453,
G496, N501
R403, Y495, F497, N501, Y505
’Compound6920 71.71 Y453, G496 R403, Q493, Y495, Y505
’Compound1110 71.58 Y453 R403, Y449, Q493, S494,
Y495, F497, N501, Y505
Abd-ElAziem Farouk, Mohammad Hassan Baig, Mohd Imran Khan et al. Saudi Journal of Biological Sciences 28 (2021) 3262–3269evaluated based on their PLP fitness score. The top 15 effective
molecules with a high binding affinity (PLP Fitness score) were
selected (Table 1). The selected most effective molecules were fur-
ther evaluated for their affinity to disrupt the interaction of SARS-
CoV-2 spike protein (RBD) with the human host receptor (ACE-2).
These 15 compounds with high binding affinity against RBD are
enlisted in Table 1. Further, the complex of top-scoring 15 mole-
cules with spike protein was prepared.3264These complexes were further subjected to PPI study against
ACE2. It was found that the presence of the above-mentioned com-
pounds affects the binding of the RBD to its natural interacting
partner, the ACE2 receptor. The selected top fifteen hits were
ranked based on their affinity to interrupt the ACE2-RBD interac-
tion (global energy). Compound 148, 6612, and 107 were found
Abd-ElAziem Farouk, Mohammad Hassan Baig, Mohd Imran Khan et al. Saudi Journal of Biological Sciences 28 (2021) 3262–3269to be the most potent inhibitors disrupting the ACE2-RBD interac-
tion. These compounds expressed a high affinity against the RBD
domain of the spike protein and were also capable of interrupting
the binding of ACE2 with RBD. Compound 148, 6612 and, 107 have
caused the reduction in the global energy of the RBD-ACE2 com-
plex from 63.99 to 38.16, 38.34 and 38.70 respectively
(Table 2 and 3, Fig. 3). The drop in the global energy score indicates
that these compounds’ presence restricts the binding of RBD-ACE-
2. This shows that the presence of compounds 148, 6612, and 107
hinders RBD’s binding to the ACE2 receptor, thereby may be a suit-
able therapeutic candidate blocking the viral entry mechanism
(Table 2, Fig. 2).
We have also investigated the role of prominent residues
involved in the binding of RBD to its receptor (ACE2) and the inhi-
bitors. The active site residues Tyrosine (Y) 449, Tyrosine (Y) 453,
Leucine (L) 455, Phenylalanine (F) 456, Phenylalanine (F) 486,
Asparagine (N) 487, Tyrosine (Y) 489, Glutamine (Q) 493, Glycine
(G) 496, Glutamine (Q) 498, Threonine (T) 500, Asparagine (N)
501, Glycine (G) 502 and Tyrosine (Y) 505 of the SARS-CoV-2 spikeTable 2
The protein–protein binding score of SARS-CoV-2 spike protein (RBD) with the human
host receptor (ACE-2) in absence and presence of selected compounds.
Complex Global energy
SARS-CoV-2 SPIKE (RBD)-ACE2 63.99
SARS-CoV-2 SPIKE (RBD)Compound59910-ACE2 40.58
SARS-CoV-2 SPIKE (RBD)’Compound66040-ACE2 41.04
SARS-CoV-2 SPIKE (RBD)’Compound66060-ACE2 48.44
SARS-CoV-2 SPIKE (RBD)’Compound66120-ACE2 38.34
SARS-CoV-2 SPIKE (RBD)’Compound960-ACE2 43.83
SARS-CoV-2 SPIKE (RBD)’Compound1100-ACE2 44.29
SARS-CoV-2 SPIKE (RBD)’Compound1070-ACE2 38.70
SARS-CoV-2 SPIKE (RBD)’Compound7240-ACE2 41.91
SARS-CoV-2 SPIKE (RBD)’Compound7080-ACE2 46.50
SARS-CoV-2 SPIKE (RBD)’Compound1060-ACE2 48.23
SARS-CoV-2 SPIKE (RBD)’Compound7030-ACE2 50.28
SARS-CoV-2 SPIKE (RBD)’Compound1480-ACE2 38.16
SARS-CoV-2 SPIKE (RBD)’Compound590-ACE2 40.11
SARS-CoV-2 SPIKE (RBD)’Compound6920-ACE2 47.63
SARS-CoV-2 SPIKE (RBD)’Compound1110-ACE2 48.28
Table 3
The active site residues involved in the protein–protein binding score of SARS-CoV-2 spi
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3265protein (RBD) were found to be involved in the binding to ACE2
receptor (Fig. 4a, Table 3). The binding of the compounds within
RBD’s active site was dominated by hydrogen bond interactions,
involving R403, Y453, G496, Q498, G502, and Y505 residues
(Table 1). Further Molecular dynamics simulation was performed
to investigate the time-dependent activity of the complexes. Des-
mond was used to perform the MD simulation for the top 3
selected complexes (in the presence of compounds 107, 148 and
6612). Among the three identifies hits, compound 6612 exhibited
greater stability while bound in the RBD-ACE-2 complex as com-
pared to compounds 148 and 107 (Fig. 4b, c). The ligand RMSD plot
revealed that Compound 148 and 6612 were very stable during
simulation, while a low fluctuation was found in compound 107
(Fig. 4b). The protein RMSD and RMSF analysis were performed
to investigate the proteins’ dynamic stability in the presence of
selected compounds. The backbone RMSD of the protein revealed
greater stability for the complexes involving compound 6612, as
compared to compound 148 and 107 (Fig. 4c). A large degree of
fluctuation was noticed in the presence of compound 107, and
the fluctuation was noticed after 6 ns (Fig. 4c). While in the pres-
ence of compound 148, fluctuation in the protein backbone RMSD
was noticed after 8 ns. Further analysis of the RMSF plot revealed a
large conformational change in the ACE2 protein of all three com-
plexes (Fig. 4d, e). These conformational changes were observed in
the residues lying far away from the interfacial binding region. The
fluctuation was very high in the compound 107 bound complex,
compared to the complexes involving other two compounds. A
high degree of fluctuation was observed for the residues 365–
385, 415–435, and the loop region residues (477–485) of RBD
(Fig. 4d).6. Discussion
The COVID-19 outbreak, caused by the SARS-CoV-2, has
strongly affected all walks of life and has become a severe public
health concern (Mattioli et al., 2020; Dong et al., 2020; Xu and Li,
2020). At present, there is no available drug or antiviral for the
treatment against SARS-CoV-2, and the development of new drug
molecules will take time (Choudhary et al., 2020). Several antivi-ke protein (RBD) with the human host receptor (ACE-2) in absence and presence of
racting residues
Spike protein
27, F28, D30, K31, H34, E35, E37,
Q42, L45, M82, Y83, N330, G352,
4, D355, R357, R393
K417, V445, G446, G447, Y449, Y453, L455,
F456, A475, P486, N487, Y489, Q493, G496,




Fig. 3. The top 3 compounds selected in the study and their RBD-ACE2 interface bound structures. The structure of ACE2 is shown in cyan color, while the structure of
Receptor binding domain (RBD) SARS-CoV-2 spike glycoprotein is in yellow color.
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gunya, dengue virus, or other RNA viruses by either blocking the
viral entry or inhibiting their replication at different stages
(Mudgal et al., 2020; Singh et al., 2018). The S protein of SARS-
CoV-2 is composed of 1273 amino acids. The initial 12 residues
at N-terminus form the signal peptides while the rest of the mature
part is proteolytically processed into two subunits (S1 & S2)
(Satarker and Nampoothiri, 2020; Chen et al., 2020). Subunit S1
comprises amino acids from 14 to 685, and residues between
686 and 1273 encodes for subunit S2 (Huang et al., 2020;
Malladi et al., 2020). The S1 subunit of the spike glycoprotein is
responsible for the host cell receptor binding (ACE-2), while the
S2 subunit is responsible for the fusion of the virus to the host cell
membrane (Huang et al., 2020; Yang et al., 2020) (Fig. 1). It has
been found that the RBD (amino acids 319–541) of the S1 subunit
of SARS-CoV-2 binds to the outer surface of ACE2 (claw-like struc-
ture) of the host (Li et al., 2005; Huang et al., 2020; Yang et al.,
2020; Yan et al., 2020; Song et al., 2018; Kirchdoerfer et al.,
2018). ACE2 is the primary host target of SARS-CoV-2 spike protein
(Yan et al., 2020). It is located on the cell’s outer surface and has
been widely reported to be the primary host cell target, thereby
playing a prominent role in the viral entry (Song et al., 2018; Ali
and Vijayan, 2020; Wu et al., 2012; Gui et al., 2017) (Fig. 1). Since
this interaction is an essential step facilitating the entry of SARS-
CoV-2 within the host cell, the compounds targeting S-RBD–ACE2
interface and thereby blocking this protein–protein interaction
could be a potential therapeutic candidate against COVID-19,
inhibiting the viral entry into host cell (Adedeji et al., 2013). The3266crystal structure of SARS-CoV-2 spike RBD bound with ACE2 was
considered for the in silico studies (Lan et al., 2020). We have uti-
lized the in silico virtual screening approach to screen the antiviral
library (Asinex) against the RBD of the SARS-CoV-2 spike glycopro-
tein. We determined the binding affinity and evaluated the binding
conformation of molecules within the RBD’s active site. The study
seeks to identify small molecules carrying inhibitory potential
against the spike protein (RBD), and they must be capable of dis-
rupting the binding of RBD-ACE-2 as well. The PPI study revealed
that the active site residues of SARS-CoV-2 spike protein (RBD)
viz. Tyrosine (Y) 449, Tyrosine (Y) 453, Leucine (L) 455, Phenylala-
nine (F) 456, Phenylalanine (F) 486, Asparagine (N) 487, Tyrosine
(Y) 489, Glutamine (Q) 493, Glycine (G) 496, Glutamine (Q) 498,
Threonine (T) 500, Asparagine (N) 501, Glycine (G) 502 and Tyro-
sine (Y) 505 were found to be involved in the binding to ACE2
receptor (Fig. 4a, and Table 3). The role of these active site residues
of RBD has been previously well defined (Lan et al., 2020; Ortega
et al., 2020; Prajapat et al., 2020). These residues were also
involved in accommodating the small molecules within the active
site of spike protein (RBD) as well. Our findings reveal high flexibil-
ity in the residues remote to the RBD interface of ACE2, and the
finding is in accordance with other earlier reports (Liu et al.,
2020). We observed that the region at the binding interface in
the ACE2-RBD complex was stable throughout the simulation com-
pared to the other areas. The ACE2 interfacing residues exhibited
minimum conformational changes. We found that the RBD-ACE2
complex was most stable in the presence of compound 6612, fol-
lowed by compound 147, while it was unstable in the presence
Fig. 4. The Molecular dynamics results of the SARS-CoV-2 spike protein (RBD) with the human host receptor (ACE-2) in presence of Compound 6612, Compound 107 and
Compound 148. The Fig. 4(a) The binding of residues within the interface region of RBD-ACE-2. Fig. 4(b) Ligand RMSD plot of all the 3 compounds in the complex. Fig. 4(c)
RMSD of protein in presence of the compounds. Fig. 4(d) The RMSF plot of ACE2 during the simulation time period. Fig. 4(e) The RMSF plot of Spike protein during the
simulation time period.
Abd-ElAziem Farouk, Mohammad Hassan Baig, Mohd Imran Khan et al. Saudi Journal of Biological Sciences 28 (2021) 3262–3269of compound 107. A high degree of fluctuation was observed for
the residues 365–385, 415–435, and the loop region residues
(477–485) of RBD (Fig. 4d). We observed the prominent involve-
ment of the residues 477–485 of the loop region at the interface
binding site, and our findings are in the right perspective as has
been reported earlier for the involvement of the residues of the
loop region binding to the ACE2 receptor (Liu et al., 2020; Brielle
et al., 2020).7. Conclusion
The Asinex antiviral library’s virtual screening against the
receptor binding domain of SARS-CoV-2 spike protein provides
us a list of several active compounds, with high binding affinity
against the receptor binding domain. The further assessment of
these compounds’ potential to inhibit the ACE2-RBD interaction
provides an additional valuable feature to them. Compound 107,
148, and 6612 were found to be the most active compounds, cap-
able of binding to RBD and interrupting the ACE2-RBD interaction3267as well. MD simulation studies showed that in the presence of
compound 6612, the ACE2-RBD complex was most stable, followed
by 107 and 148. The importance of essential residues has also been
explored in this study. It was noticed that the conformational
changes were majorly in the residues far away (remote) from the
interface region of ACE2. The information provided will be of great
help in using these compounds as possible drug candidates against
COVID-19, and may also help for future drug discovery.Funding
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